Evidence map›Paper›PMID 36696843›Full record

Trial reportDrug and alcohol dependence2023

Self-report and urine drug screen concordance among women with co-occurring PTSD and substance use disorders participating in a clinical trial: Impact of drug type and participant characteristics.

L M Ruglass, A Shevorykin, Y Zhao, T K Killeen, A G Bauer, A A Morgan-López, S E Back, S Fitzpatrick, T López-Castro, S B Norman and 2 more

Open access · greenAbstract readClinical Trial
In one paragraph

Trial report in Drug and alcohol dependence, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 2 countries.

L M RuglassDepartment of Psychology, The City College of New York, CUNY, USA; Center of Alcohol and Substance Use Studies, Rutgers University-New Brunswick, USA. Electronic address: ruglass.ccny@gmail.com.
A ShevorykinDepartment of Health Behavior, Roswell Comprehensive Cancer Center, USA.
Y ZhaoCenter of Alcohol and Substance Use Studies, Rutgers University-New Brunswick, USA; School of Nursing, Columbia University, USA; Department of Psychiatry, Yale University School of Medicine, USA.
T K KilleenDepartment of Psychiatry and Behavioral Sciences, Medical University of South Carolina, USA.
A G BauerCenter of Alcohol and Substance Use Studies, Rutgers University-New Brunswick, USA.
A A Morgan-LópezRTI International, USA.
S E BackDepartment of Psychiatry and Behavioral Sciences, Medical University of South Carolina, USA.
S FitzpatrickDepartment of Psychology, York University, Canada.
T López-CastroDepartment of Psychology, The City College of New York, CUNY, USA.
S B NormanNational Center for PTSD, White River Junction, VT, USA; Department of Psychiatry, University of California, San Diego, USA.
L M SaavedraRTI International, USA.
D A HienCenter of Alcohol and Substance Use Studies, Rutgers University-New Brunswick, USA.
Rutgers, The State University of New Jersey · USMedical University of South Carolina · USRTI International · USCity College of New York · USColumbia University · USUniversity of California, San Diego · USYork University · CA

Funding

Project-003UG1DA013035 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aimee N Campbell, Jennifer McNeely · 2015 to 2026
$130.3M
FLORIDA NODE OF THE DRUG ABUSE CLINICAL TRIALS NETWORKU10DA013720 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI METSCH, LISA R, SZAPOCZNIK, JOSE · 2000 to 2015
$56.9M
CU PARTNERS: NY/LONG ISLAND REGIONAL NODEU10DA013035 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI NUNES, EDWARD V., ROTROSEN, JOHN P · 2001 to 2015
$47.6M
Clinical Trials Network, Ohio Valley Node U10DA013732U10DA013732 · NIDA · UNIVERSITY OF CINCINNATI · PI WINHUSEN, T JOHN · 2000 to 2015
$45.0M
Southern Consortium Node of the Clinical Trials NetworkU10DA013727 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T. · 2000 to 2015
$34.4M
CLINICAL TRIALS NETWORK: PACIFIC NORTHWEST NODEU10DA013714 · NIDA · UNIVERSITY OF WASHINGTON · PI DONOVAN, DENNIS MICHAEL, ROLL, JOHN M. · 2001 to 2015
$25.5M
NIDA CLINICAL TRIALS NETWORK - NYC EAST SIDE NODEU10DA013046 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ROTROSEN, JOHN P · 2000 to 2009
$20.2M
CLINICAL TRIALS NETWORK: NEW ENGLAND NODEU10DA013038 · NIDA · YALE UNIVERSITY · PI CARROLL, KATHLEEN M. · 1999 to 2010
$17.3M
Training Program on HIV and Substance Use in the Criminal Justice SystemT32DA037801 · NIDA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Nabila El-Bassel, Lisa R Metsch · 2014 to 2026
$5.7M
Translational Research Training on Addictions for Racial/Ethnic MinoritiesR25DA035161 · NIDA · CITY COLLEGE OF NEW YORK · PI DENISE AIMEE HIEN, Lesia Monique Ruglass · 2013 to 2026
$4.4M
Meta-analysis of Individual Patient Data for PTSD/AODsR01AA025853 · NIAAA · RESEARCH TRIANGLE INSTITUTE · PI HIEN, DENISE AIMEE, MORGAN-LOPEZ, ANTONIO A · 2018 to 2021
$1.7M
NIAAA NIH HHS R01 AA025853NIDA NIH HHS R25 DA035161NIDA NIH HHS T32 DA037801NIDA NIH HHS U10 DA013035NIDA NIH HHS U10 DA013038NIDA NIH HHS U10 DA013046NIDA NIH HHS U10 DA013714NIDA NIH HHS U10 DA013720NIDA NIH HHS U10 DA013727NIDA NIH HHS U10 DA013732NIDA NIH HHS UG1 DA013035
6 · The paper itself

Abstract

backgroundSelf-report measures are important in substance use assessment, yet they are susceptible to reporting errors. Urine drug screens (UDS) are often considered a more valid alternative. However, collecting in-person UDS may not always be feasible, contributing to the need to understand factors that influence the validity of self-reported substance use.

methodsIn this secondary analysis of data from 295 women with co-occurring PTSD and substance use disorders (SUD) who participated in a clinical trial testing behavioral interventions, we examined concordance and discordance between self-reported drug use and associated UDS results. Generalized linear mixed models were used to examine the impact of treatment type and participant characteristics on the associations between self-reported drug use and UDS results.

resultsFindings revealed higher disagreement between self-report and UDS for opioids and sedatives (ranging from.77 to.90) and lower disagreement rates for cannabis and cocaine (ranging from.26 to.33). Treatment type was not a significant moderator of the associations between self-report and UDS across all drugs. Among those with a positive opioid UDS, those who reported employment in the past three years were more likely to self-report no opioid use compared to their counterparts without employment in the past three years.

conclusionsFindings add to the literature that supports the validity of self-reported cannabis and cocaine use. The greater discrepancies between self-report and UDS test results of opioids and sedatives suggest adjunctive UDS may be required, although a variety of factors other than inaccurate self-report may be associated with this discrepancy.

Indexed as

CannabisCocaineOpioid-Related DisordersStress Disorders, Post-TraumaticSubstance-Related DisordersAnalgesics, OpioidFemaleHumansHypnotics and SedativesSelf ReportSubstance Abuse DetectionAnalgesics, OpioidCocaineHypnotics and SedativesPTSDSelf-reportSubstance use disorderTreatmentUrine drug screenWomen

Identifiers

PMID36696843
PMCPMC9987239
OpenAlexW4316126875

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.